Efficacy and toxicity of pegylated liposomal doxorubicin‐based chemotherapy in early‐stage breast cancer: a multicenter retrospective case–control study

PEGylated liposomal doxorubicin (PLD) has comparable efficacy and differing toxicity from conventional anthracyclines used to treat advanced breast cancer. This study compared disease‐free survival and toxicity between PLD‐based and conventional anthracycline‐based regimens as adjuvant treatments for early‐stage breast cancer.

[1]  Jin-Hwang Liu,et al.  A Dose-Escalating Pilot Study of Sterically Stabilized, Pegylated Liposomal Doxorubicin (Lipo-Dox®) in Patients with Metastatic Breast Cancer , 2003, Cancer investigation.

[2]  M. Piccart,et al.  Long-term toxic effects of adjuvant chemotherapy in breast cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  E. Perez,et al.  Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[6]  G. Scambia,et al.  Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  M. Adamcová,et al.  Anthracycline-induced cardiotoxicity. , 2000, Acta medica.

[8]  H. Shmeeda,et al.  An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin , 2008, Cancer Chemotherapy and Pharmacology.

[9]  M. Rossing,et al.  Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients , 2007, Breast Cancer Research.

[10]  T. Delozier,et al.  Phase II Trial of Pegylated Liposomal Doxorubicin-Cyclophosphamide Combination as First-Line Chemotherapy in Older Metastatic Breast Cancer Patients , 2008, Oncology.

[11]  A. Moreno-Aspitia,et al.  Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines. , 2014, World journal of clinical oncology.

[12]  Liposomal anthracyclines in metastatic breast cancer: clinical update. , 2003, The oncologist.

[13]  J. Bergh,et al.  Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Hortobagyi,et al.  Anthracyclines in the Treatment of Cancer , 2012, Drugs.

[15]  D. Ahmann,et al.  Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. , 1974, Cancer chemotherapy reports.

[16]  J. Goodwin,et al.  Decline in the use of anthracyclines for breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[18]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[19]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[20]  N. Habboubi,et al.  Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. , 1993, Cancer treatment reviews.

[21]  J. Bryant,et al.  Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  D. V. Von Hoff,et al.  Risk factors for doxorubicin-induced congestive heart failure. , 1979, Annals of internal medicine.

[23]  Early Breast Cancer Trialists' Collaborative Group.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.

[24]  A. Birtle.  Anthracyclines and cardiotoxicity. , 2000, Clinical oncology (Royal College of Radiologists (Great Britain)).

[25]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[26]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[27]  P. Wilkinson,et al.  A Preliminary Trial of Doxorubicin in Advanced Breast Cancer and Other Malignant Disease , 1974, British Journal of Cancer.